Last Price
2.95
Today's Change
+0.20 (7.27%)
Day's Change
2.55 - 3.02
Trading Volume
237,097
Exchange: Nasdaq Nasdaq
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Peter O'Heeron Mr. Peter O'Heeron
Full Time Employees: 10 10
IPO Date: 2024-02-01 2024-02-01
CIK: 0001958777 0001958777
ISIN: US31573L1052 US31573L1052
Beta: 0.00 0.00
Last Dividend: 0.00 0.00
Dcf Diff: 2.60 2.60
Dcf: 0.26 0.26
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.